TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Expected to Rise, HC Wainwright Analyst Says

Posted by Teresa Graham on Dec 19th, 2024

TransCode Therapeutics (NASDAQ:RNAZ – Free Report) had its target price lifted by HC Wainwright from $3.00 to $20.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

TransCode Therapeutics Price Performance

Shares of TransCode Therapeutics stock opened at $3.92 on Wednesday. TransCode Therapeutics has a twelve month low of $3.21 and a twelve month high of $264.00. The company’s fifty day moving average is $411.36 and its 200 day moving average is $569.65.

Hedge Funds Weigh In On TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management raised its position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) by 149.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent quarter.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.